Step Down Deductible

Earlier this year, Tokio Marine HCC – Stop Loss Group (TMHCC) released a much-needed product solution for gene therapy treatments that benefits our policyholders through a step down deductible. We want to thank you for the 400+ business partners that attended our webinar announcing the rollout of this product offering. If you missed it, you can view a recording of it here.

As a recap, TMHCC partnered with Emerging Therapy Solutions (ETS) to offer a solution for managing the high costs of cell and gene therapy treatments. Through implementation of the suggested Plan Document language provided by ETS, TMHCC stop loss policyholders will receive a 10% reduction in the specific deductible for the patient receiving gene therapy through an ETS program. The 10% step down deductible has a minimum of $15,000 and a maximum of $50,000, making the percentage more than 10% for groups with specific deductibles under $150,000. TMHCC will also cover the ETS access fee for utilizing their services.

Please refer to TMHCC's Best Practices in Cell & Gene Therapy for details on how the step down deductible can save your clients' money on gene therapy treatments.

Contact your regional marketing representative to learn more on how TMHCC’s partnership with ETS can positively impact your clients’ healthcare plans.



For producer use only. Not for public distribution.
Copyright 2020, Tokio Marine HCC. Tokio Marine HCC is a member of the Tokio Marine Group of Companies.

Tokio Marine HCC - Stop Loss Group | Corporate Headquarters | 225 TownPark Drive NW, Suite 350 | Kennesaw, GA 30144

Tokio Marine HCC - Stop Loss Group respects your privacy. We do not rent, sell or exchange email addresses. Please see our Privacy Policy for more information. If you do not wish to receive any emails concerning Tokio Marine HCC - Stop Loss Group's policies, changes and events, please click below to unsubscribe.

Click here to unsubscribe to all emails from TMHCC.


TMHCC-E2072 100120